- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 31/14 - Antivirals for RNA viruses
Patent holdings for IPC class A61P 31/14
Total number of patents in this class: 10492
10-year publication summary
173
|
170
|
185
|
271
|
378
|
407
|
1771
|
1941
|
2099
|
466
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Gilead Sciences, Inc. | 1879 |
109 |
Bristol-myers Squibb Company | 5080 |
87 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
82 |
The Regents of the University of California | 18943 |
77 |
Janssen Pharmaceuticals, Inc. | 399 |
64 |
Centre National de La Recherche Scientifique | 9632 |
63 |
Katholieke Universiteit Leuven | 1035 |
59 |
Enanta Pharmaceuticals, Inc. | 420 |
58 |
Modernatx, Inc. | 1181 |
56 |
Inserm (institut National de La Sante et de La Recherche Medicale) | 3314 |
51 |
The Trustees of the University of Pennsylvania | 4122 |
47 |
Emory University | 1498 |
44 |
Pfizer Inc. | 3322 |
43 |
Vanderbilt University | 1731 |
42 |
BioNTech SE | 482 |
41 |
Abbvie Inc. | 1808 |
40 |
Institut Pasteur | 798 |
40 |
The Board of Trustees of the Leland Stanford Junior University | 6054 |
37 |
Takeda Vaccines, Inc. | 199 |
37 |
Merck Sharp & Dohme Corp. | 2247 |
36 |
Other owners | 9379 |